Tango Therapeutics, Inc. (TNGX)
TNGX moved a median of +0.41% 30 minutes after news, and 0.00% by the close. How TNGX actually reacts to news — the realized, point-in-time move the market made, measured across 309 labeled events over the last three years with zero look-ahead.
TNGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.27% | 57% | 308 |
| 30-min | +0.41% | 56% | 309 |
| 60-min | 0.00% | 48% | 309 |
| to close | 0.00% | 50% | 307 |
| Middle 50% of TNGX reactions | -0.93% to +1.89% |
|---|---|
| Median reaction (30-min) | +0.41% |
| Measured reactions | 309 |
Half of all Tango Therapeutics, Inc. news events land between -0.93% and +1.89% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TNGX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -1.39% | 36% | +1.13% |
| Analyst downgrades | 11 | -1.83% | 18% | -2.95% |
| Coverage initiations | 30 | -0.63% | 40% | +1.61% |
| Rating reiterations | 53 | -0.31% | 49% | +1.00% |
| Price-target raises | 18 | +0.02% | 50% | +0.66% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how TNGX ranks against every other measured name →
That’s how TNGX usually reacts — get an email when it moves on news →Email me when TNGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TNGX's baseline. Nothing else.
Recent TNGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | Press release | GlobeNewswire | -0.52% | -3.92% | |
| Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.62% | +0.18% | |
| Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | +1.20% | -1.11% | |
| Form 10-Q Tango Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | -2.63% | |
| Form 8-K Tango Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -2.63% | |
| Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | +0.79% | -2.63% | |
| Form 8-K/A Tango Therapeutics, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -5.71% | |
| Form 8-K Tango Therapeutics, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -5.71% | |
| Tango Therapeutics Announces Executive Chair Transition | Press release | GlobeNewswire | +0.14% | -5.71% | |
| Form 8-K Tango Therapeutics, Inc. For: Jun 19 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | +2.50% | |
| Tango Therapeutics Appoints Robert Azelby to Board of Directors | Press release | GlobeNewswire | +3.07% | +1.36% | |
| Form 8-K Tango Therapeutics, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | +4.52% | |
| Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering | Press release | GlobeNewswire | -6.49% | -9.38% | |
| Form 8-K Tango Therapeutics, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -3.67% | +3.10% | |
| Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer | Press release | GlobeNewswire | -3.67% | +3.10% | |
| Tango Therapeutics Announces Proposed $500 Million Public Offering | Press release | GlobeNewswire | -1.66% | -2.08% | |
| Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.36% | -8.17% | |
| Form 8-K Tango Therapeutics, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -8.17% | |
| Form 10-Q Tango Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.47% | +2.77% | |
| Form 8-K Tango Therapeutics, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | +2.77% | |
| Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | +1.47% | +2.77% | |
| Form 8-K Tango Therapeutics, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -2.91% | |
| Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.87% | +5.72% | |
| Form ARS Tango Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.03% | +5.25% | |
| Form DEF 14A Tango Therapeutics, Inc. For: Apr 16 | SEC filing · Form DEF | SEC EDGAR | +1.03% | +5.25% | |
| Form DEFA14A Tango Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.03% | +5.25% | |
| Form 8-K Tango Therapeutics, Inc. For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +5.81% | |
| Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | Press release | GlobeNewswire | +0.79% | +5.81% | |
| Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.89% | -2.95% | |
| Form 10-K Tango Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.74% | +37.95% | |
| Form 8-K Tango Therapeutics, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | +37.95% | |
| Form S-8 Tango Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.74% | +37.95% | |
| Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | -0.74% | +37.95% | |
| Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | +0.86% | -3.35% | |
| Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +0.25% | +5.29% | |
| Form 8-K Tango Therapeutics, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | +0.41% | |
| Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Press release | GlobeNewswire | -1.73% | +0.41% | |
| Form 8-K Tango Therapeutics, Inc. For: Jan 02 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -1.00% | |
| Tango Therapeutics Appoints Sung Lee to Board of Directors | Press release | GlobeNewswire | -0.06% | -1.00% | |
| Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.89% | -2.23% | |
| Form EFFECT Tango Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.49% | -0.76% | |
| Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.38% | +1.80% | |
| Form 8-K Tango Therapeutics, Inc. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +6.15% | +16.36% | |
| Form S-3 Tango Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +6.15% | +16.36% | |
| Form S-3ASR Tango Therapeutics, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +6.15% | +16.36% | |
| Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +1.30% | -9.23% | |
| Form 10-Q Tango Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.89% | +1.52% | |
| Form 8-K Tango Therapeutics, Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +1.52% | |
| Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | +0.89% | +1.52% | |
| Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | Press release | GlobeNewswire | -2.70% | +0.64% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TNGX section they belong to.
Where else TNGX is measured.
TNGX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tango Therapeutics, Inc.'s median reaction calculated?
Every labeled TNGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 309 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of TNGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TNGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.